Consequently, ICIs can reinstate the tumor immune microenvironment by blocking the binding of PD-1 and its ligands between tumor cells and T cells and restoring the toxic effect of T cells to achieve tumor suppression. The gene discussed is PDCD1; the disease is neoplasm.